Navigation Links
Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results
Date:5/9/2011

t-family:Arial;font-size:8pt;">$
.62$
.59
Non-GAAP benefit from the out-license of Cloderm (e)$
.06
Adjusted Non-GAAP (Cash) earnings per share - diluted (excluding the Non-GAAP benefit from the out-license of Cloderm) (e)$
.56
Shares used in diluted per share calculation - GAAP earnings per share332,900158,387Shares used in diluted per share calculation - Adjusted Non-GAAP (Cash) earnings per share332,900159,205(a) Prior year non-GAAP adjustments have been modified to conform to the 2011 disclosure.(b) To supplement the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the company uses non-GAAP financial measures that exclude certain items, such as amortization of inventory step-up, amortization of alliance product assets & pp&e step up, stock-based compensation step-up, restructuring and acquisition-related costs, acquired in-process research and development ("IPR&D"), legal settlements outside the ordinary course of business, the impact of currency fluctuations, acquisitions, amortization and other non-cash charges, amortization of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest, loss on extinguishment of debt, (gain) loss on investments, net, and adjusts tax expense to cash taxes. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP
'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
8. Valeant Announces Pricing of Senior Notes
9. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
10. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
11. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014   Santa Clara dentist , Dr. ... for Invisalign. Invisalign is an orthodontic system that uses ... often the orthodontic treatment of choice for older teens ... it. For a limited time, patients can try Invisalign ... the usual cost. This offer cannot be combined, and ...
(Date:9/2/2014)... 2014 -- ... het ESC CONGRESS 2014 geven inzicht in ... op beroerte in de dagelijkse klinische praktijk ... 12.500 patiënten ingeschreven in de Global Anticoagulant ... innovatief, onafhankelijk initiatief op het gebied van ...
(Date:9/2/2014)... , September 2, 2014 ... Column Market by Type (Empty, Pre-packed, Analytical, Preparative), by Material (Metal, ... Chromatography, UFLC), TLC,SFC] - Forecast to 2018", published by MarketsandMarkets, ... in 2013. It is poised to grow at a ... by 2018. Browse 90 market data ...
Breaking Medicine Technology:Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 3Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 4Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 5Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 6Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 7Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 9Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 10Chiral Chromatography Column Market Worth $87.8 Million by 2018 2Chiral Chromatography Column Market Worth $87.8 Million by 2018 3Chiral Chromatography Column Market Worth $87.8 Million by 2018 4
... Mylan Inc. (Nasdaq: MYL ) today announced ... from the U.S. Food and Drug Administration (FDA) for ... Levodopa Tablets USP, 10mg/100mg, 25mg/100mg and 25mg/250 mg. , ... Bristol Myers Squibb,s Parkinson,s treatment Sinemet®, 10mg/100mg, 25mg/100mg and ...
... JERUSALEM, Israel, September 30 Gamida Cell ... generic,name of what is widely known as "StemEx", as ... The article, carlecortemcel-l, an ex vivo expanded,umbilical cord blood ... Chan and Dr. Demetrios Petropoulos, will be published in ...
Cached Medicine Technology:Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 2Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 3
(Date:9/3/2014)... (PRWEB) September 03, 2014 Ohio ... living options and innovative services for older adults, has ... Moore Health Care Center , (Sarah Moore HCC) effective ... of experience in the health care industry, including serving ... Ohio including the MacIntosh Company and HCR Manor Care. ...
(Date:9/3/2014)... September 03, 2014 An inspiring story ... be documented in the season finale of “Extreme Weight ... and his teenage daughter from Highlands Ranch, Colo. who ... she weighs 265 pounds. Their challenge is to team ... Featuring a unique, non-competitive approach to weight loss transformations, ...
(Date:9/3/2014)... Health information technology improves the ... medical errors, and strengthens the interaction between patients ... important role health information technology plays in improving ... the U.S. have joined together to celebrate National ... 2014. With the NHIT Week theme: One Voice, ...
(Date:9/3/2014)... September 03, 2014 Independent review ... of appropriate evidence-based health care along the continuum. ... from the expertise of accredited independent review organizations ... care system. , As a core function, IROs ... settle questions of medical necessity. Yet backed by ...
(Date:9/2/2014)... 03, 2014 IMCA Speedway Motors Super ... on September 1, 2014 at the IMCA Speedway in ... ceremony will include a check presentation to Hope For ... is a national nonprofit organization that assists post-9/11 service ... have sustained physical and psychological wounds in the line ...
Breaking Medicine News(10 mins):Health News:Arnett to Lead Delaware’s Sarah Moore Health Care Center 2Health News:“Extreme Weight Loss”: Jeff and Juliana’s Journey begin at the University of Colorado Anschutz Health and Wellness Center 2Health News:Innovative Healthcare Solutions (IHS) Celebrates National Health IT Week September, 15-19, 2014 2Health News:Independent Review Expands Its Scope: Case Studies in Context 2Health News:Independent Review Expands Its Scope: Case Studies in Context 3Health News:IMCA to Present Donation to Hope For The Warriors 2
... Healthcare Realty,Trust Incorporated (NYSE: HR ) today ... ended September 30, 2008. This dividend, in the,amount ... 3, 2008 to shareholders,of record on November 19, ... estate investment trust that,integrates owning, managing and developing ...
... Safety Foundation,(NPSF) today announced that AmerisourceBergen has joined ... solutions providers to work,alongside the Foundation, health care ... all with the single convergent goal of,making patient ... "We are excited to be a part of ...
... (MTX) is commonly used to treat rheumatoid arthritis (RA) ... the disease. Despite its widespread use, the understanding of ... joint damage occurs early in the course of RA ... for stable levels of MTX to be reached could ...
... PITTSBURGH, Nov. 4 Mylan Inc. (NYSE: ... Inc. received,final approval from the U.S. Food and ... (ANDA) for Levetiracetam Tablets, 250 mg,500 mg and ... of UCB,Pharma,s Keppra(R)., Robert J. Coury, Mylan,s ...
... 4 BeaconEquity.com announces the,availability of Trade Alerts on ... of the daily trading notes for free by visiting:, ... Inc. (NYSE: WMT ),Advanced Medical Optics Inc. (NYSE: ... Inc. (NYSE: EXP ), QLogic Corp. (Nasdaq: ...
... (San Francisco, CA,and Ottawa, Canada) a clinical-stage biopharmaceutical company, ... Executive Officer,will present an overview of the Company at ... York on November 11, 2008 at 3:15 p.m. Eastern,Time ... York., A webcast of the presentation will be ...
Cached Medicine News:Health News:Healthcare Realty Trust Announces Third Quarter Dividend 2Health News:AmerisourceBergen Joins National Patient Safety Foundation Corporate Council 2Health News:Wide variability in rheumatoid arthritis drug suggests alternative dosing should be considered 2Health News:Wide variability in rheumatoid arthritis drug suggests alternative dosing should be considered 3Health News:Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately 2Health News:Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: WMT, EYE, ESRX, EXP, QLGC, NSM 2Health News:Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: WMT, EYE, ESRX, EXP, QLGC, NSM 3Health News:Jennerex To Present at Rodman & Renshaw 10th Annual Healthcare Conference 2
... Foot Control allows hands-free operation in nerve ... or 5.0 mA) with SoloStim provides a ... fine control when close to nerve., ... nerve block products, including the clinically proven ...
... ,The Centiva/5 Critical Care Ventilator is your solution ... critical care environment. The Centiva has been designed ... size with high levels of performance. The Centivas ... patients bed and allows you the freedom to ...
... Mesh Elastic is a lightweight and large pore ... mesh is able to adapt to all movements ... honeycomb like structure with the large pores enables ... The mesh is ideal for incisional hernia repair ...
... a mesh plug to treat large or ... hernias and femoralhernias. The self-expanding plug perfectly ... completely. Premilene Mesh Self-Forming Plug is a ... Mesh. The plug corresponds with all properties ...
Medicine Products: